Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases

  • Insights

  • Biotech Market / Business Intelligence

Sotio Biotech

15/10/2024

September 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Share on social networks

Share on social networks

Print

Copy link

Market

Slow IPO season may be coming to an end, as four biotechs completed IPO of $100+ million

A slow season for biotech IPOs may be coming to an end. In September, four biopharmas have completed NASDAQ listings in which each raised more than $100 million, including Bicara with $315 million IPO. Most recently, Upstream Bio filed for IPO seeking to raise $100 million.

News detail

Antibody-Drug Conjugates

Patritumab-Dx demonstrates a statistically significant Ph 3 PFS improvement in NSCLC

The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated NSCLC who received prior EGFR TKI treatment met its primary endpoint of PFS, demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy. 

News detail

Interleukin-15 and Interleukin-2

ImmunityBio presented positive long-term OS data of Anktiva in NSCLC

ImmunityBio announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced NSCLC being treated with checkpoint inhibitors.

News detail

Cell Therapies

ArsenalBio announced $325 million financing to advance cell therapy programs

Arsenal Biosciences, a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round.

News detail

Other Innovative Treatment Areas

Rybrevant plus chemotherapy show 49 % ORR in metastatic colorectal cancer

JNJ announced new data from the Phase 1b/2 OrigAMI-1 study, which showed Rybrevant (amivantamab-vmjw) combined with chemotherapy demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic CRC who have not previously received anti-EGFR therapy.

News detail

DISCLAIMER / SOTIO

Legal Notice

News detail